{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:24:47Z","timestamp":1791951887703,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijrobp.2026.06.3080","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:23:08Z","timestamp":1783725788000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute Toxicity and Quality of Life With Stereotactic Body Radiation Therapy Versus Conventional Fractionated Intensity Modulated Radiation Therapy to the Prostate and Pelvis in High-Risk Prostate Cancer: A Randomized Phase 2 Trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-0743","authenticated-orcid":false,"given":"Darren M.C.","family":"Poon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk-Man","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0002","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0003","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0004","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: Long-term update of NRG Oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0005","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0006","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(25)00034-8","article-title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): An individual patient data meta-analysis of randomised trials in the MARCAP consortium","volume":"26","author":"Kishan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0008","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): Early toxicity and quality of life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0009","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","article-title":"A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer","volume":"92","author":"Bauman","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0010","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A randomized feasibility trial of stereotactic prostate radiation therapy with or without elective nodal irradiation in high-risk localized prostate cancer (SPORT Trial)","volume":"117","author":"Houlihan","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2026.06.3080_bib0011","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.ijrobp.2022.07.588","article-title":"Five-fraction stereotactic ablative radiotherapy to the pelvis and prostate with focal intra-prostatic boost: Outcomes of the 5STAR trial","volume":"114","author":"Correa","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0012","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2024.12.018","article-title":"Pelvic regional control with 25 Gy in 5 fractions in stereotactic radiation therapy for high-risk prostate cancer: Pooled prospective outcomes from the SHARP consortium","volume":"122","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0014","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0015","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.292.7.821","article-title":"6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial","volume":"292","author":"D'Amico","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0016","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2025.4800","article-title":"Optimal duration of androgen deprivation therapy with definitive radiotherapy for localized prostate cancer: A meta-analysis","volume":"12","author":"Zaorsky","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0017","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.ijrobp.2026.06.3080_bib0018","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0019","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"issue":"suppl 1","key":"10.1016\/j.ijrobp.2026.06.3080_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ajco.12855","article-title":"Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite","volume":"14","author":"Lee","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0021","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/j.juro.2016.10.071","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia","volume":"197","author":"Barry","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0022","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0023","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0360-3016(03)00132-9","article-title":"What hypofractionated protocols should be tested for prostate cancer?","volume":"56","author":"Fowler","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0024","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0025","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ijrobp.2022.04.008","article-title":"Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer","volume":"113","author":"Viani","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0026","first-page":"702","article-title":"Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology","volume":"7","author":"Bentzen","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0027","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2016.00167","article-title":"Proctitis 1 week after stereotactic body radiation therapy for prostate cancer: Implications for clinical trial design","volume":"6","author":"Paydar","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0028","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fonc.2015.00048","article-title":"Dose-escalated robotic SBRT for stage I-II prostate cancer","volume":"5","author":"Meier","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3080_bib0029","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4161\/cbt.27822","article-title":"Strategic evaluation of interventions to prevent consequential late proctitis after prostate radiation therapy: new clinical trial designs should be considered","volume":"15","author":"Showalter","year":"2014","journal-title":"Cancer Biol Ther"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626039416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626039416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:29:02Z","timestamp":1785968942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626039416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"alternative-id":["S0360301626039416"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.06.3080","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Toxicity and Quality of Life With Stereotactic Body Radiation Therapy Versus Conventional Fractionated Intensity Modulated Radiation Therapy to the Prostate and Pelvis in High-Risk Prostate Cancer: A Randomized Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.06.3080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}